SRL
NKTR icon

Scientech Research LLC’s Nektar Therapeutics NKTR Stock Holding History

Scientech Research LLC’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$794K Buy
+11,032
New +$628K 0.66% 24
2024
Q1 		– Sell
-2,015
Closed -$17.1K – 521
2023
Q4 		$17.1K Buy
+2,015
New +$15.3K 0.02% 299

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Scientech Research LLC's NKTR Position: Q1 2026 in Review

Scientech Research LLC opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 11,032 shares worth $794K. The stake represents 0.66% of the portfolio and ranks #24 among its holdings. This is a return to the name: Scientech Research LLC previously reported a position in NKTR as recently as Q4 2023.

Scientech Research LLC first reported a position in NKTR in Q4 2023 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Scientech Research LLC held 11,032 shares of Nektar Therapeutics worth $794K as of Q1 2026.
  • Nektar Therapeutics was a new Scientech Research LLC position in Q1 2026.
  • Nektar Therapeutics made up 0.66% of Scientech Research LLC's portfolio in Q1 2026, its #24 holding.
  • Scientech Research LLC first reported a position in Nektar Therapeutics in Q4 2023 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Scientech Research LLC's 13F filing for Q1 2026, filed 15 May 2026.